Pacira | PCRX - Ebitda

Stock Price
22.64
Daily Change
-0.89 -3.78%
Monthly
-5.11%
Yearly
-12.45%
Q2 Forecast
22.18

Pacira reported $40.24M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Astellas Pharma JPY 98.93B 84.75B Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
J&J USD 7.19B 2.32B Dec/2025
Ligand Pharmaceuticals USD 66.78M 83.54M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novo Nordisk DKK 34.72B 2.57B Mar/2026
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 40.24M 1.53M Mar/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Supernus Pharmaceuticals USD 29.23M 19.27M Mar/2026
Teva Pharmaceutical Industries USD 1.06B 582M Mar/2026
Xeris Pharmaceuticals USD 25.09M 7.67M Dec/2025
Xoma USD 2.52M 7.98M Jun/2024
Zoetis USD 939M 101M Dec/2025